key: cord-0690458-wwwzlfnq authors: Xiao, Jie; Zhang, Ben; Su, Zhengchen; Liu, Yakun; Shelite, Thomas R.; Chang, Qing; Qiu, Yuan; Bei, Jiani; Wang, Pingyuan; Bukreyev, Alexander; Soong, Lynn; Jin, Yang; Ksiazek, Thomas; Gaitas, Angelo; Rossi, Shannan L.; Zhou, Jia; Laposata, Michael; Saito, Tais B.; Gong, Bin title: Intracellular receptor EPAC regulates von Willebrand factor secretion from endothelial cells in a PI3K/eNOS-dependent manner during inflammation date: 2021-10-20 journal: J Biol Chem DOI: 10.1016/j.jbc.2021.101315 sha: 67a33b766a8a892c36b96672c378c0f45e619af0 doc_id: 690458 cord_uid: wwwzlfnq Coagulopathy is associated with both inflammation and infection, including infection with novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. Clot formation is promoted via cyclic adenosine monophosphate (cAMP)-mediated secretion of von Willebrand factor (vWF), which fine tunes the process of hemostasis. The exchange protein directly activated by cAMP (EPAC) is a ubiquitously expressed intracellular cAMP receptor that plays a regulatory role in suppressing inflammation. To assess whether EPAC could regulate vWF release during inflammation, we utilized our EPAC1-null mouse model and revealed increased secretion of vWF in endotoxemic mice in the absence of the EPAC1 gene. Pharmacological inhibition of EPAC1 in vitro mimicked the EPAC1-/- phenotype. In addition, EPAC1 regulated tumor necrosis factor-α (TNFα)-triggered vWF secretion from human umbilical vein endothelial cells (HUVECs) in a manner dependent upon inflammatory effector molecules phosphoinositide 3-kinase (PI3K) and endothelial nitric oxide synthase (eNOS). Furthermore, EPAC1 activation reduced inflammation-triggered vWF release, both in vivo and in vitro. Our data delineate a novel regulatory role for EPAC1 in vWF secretion and shed light on the potential development of new strategies to control thrombosis during inflammation. Accumulating evidence has suggested an extensive cross-talk between coagulation and inflammation, whereby inflammation leads to activation of coagulation that also considerably affects inflammatory activity (17) (18) (19) . Systemic infectious diseases can activate ECs and propagate immune responses and inflammation in blood vessels, increasing the risk of microthrombosis, which has been documented in lethal and non-lethal COVID-19 cases (1) (2) (3) (4) (5) . The membrane-associated, adhesive glycoprotein vWF is synthesized in ECs and megakaryocytes, and its main function is to directly promote clot formation by capturing platelets and chaperoning clotting factor VIII (20) (21) (22) . Current research has confirmed that vWF is both a plasma glycoprotein known for its role in blood clotting and a modulator of inflammatory responses (23) (24) (25) (26) (27) . A fundamental mechanism that ECs employ to regulate coagulation is by secreting von Willebrand factor (vWF) in elongated secretory organelles known as Weibel-Palade bodies (WPBs) (21, 22, 28, 29) . WBPs is under tight control (20, 34, 35 In testing the constitutive plasma levels of vWF, we observed no difference between wild-type (WT) and EPAC1-KO mice ( Figure 1A) . The difference in vWF mRNA expression between these two mouse strains was not significant ( Figure 1B) Figure 1A) . However, the change in vWF mRNA expression in lung and liver tissues was not significant (Figure 1B) Figure S1A ). Since vWF performs critical functions in primary hemostasis, a tail bleeding time test was conducted (54). The bleeding time of LPS-treated EPAC1-KO mice was shorter than that of LPS-treated WT mice ( Figure 1E ). The total blood loss, assessed by its hemoglobin content, corresponded closely with the observed bleeding time of LPStreated EPAC1-KO and WT mice ( Figure 1F ). Prothrombin time (PT) and activated partial thromboplastin time (aPTT) were also detected. There was no significant difference between the groups ( Figure S2) Figure 1H ). In conclusion, EPAC1-KO mice show a higher level of plasma vWF than WT mice in a state of inflammation in which microthrombi progression is detectable. Figure 3B ). However, I942 limits the rTNFα- We next assessed whether P-selectin is No difference in iNOS mRNA levels was observed among these groups ( Figure S4) . Statistical significance was determined using a Student's t-test or one-way analysis of variance (ANOVA). Results were regarded as significant if two-tailed P values were < 0.05. All data are expressed as mean ± standard error (SE) of the mean. All data are included within the article or the supporting information. We a The left lungs were collected for RNA extraction, and the right lungs were fixed for histopathology studies. Tissue sections of lungs, livers, and brains were stained with hematoxylin and eosin (H&E). For animals in which thrombi were detected in lungs by H&E staining using 100X power microscopy, sections were further validated with immunofluorescent staining against fibrin using rabbit anti-mouse fibrin(ogen) polyclonal antibody as described (7). Score of 3: microthrombi could be detected in any sections of the above three organs; Score of 2: microthrombi could be detected in any sections of the above two organs; Score of 1: microthrombi could be detected in only one section of the above organs; Score of 0: no microthrombi could be detected in any sections of the above organs. No thrombus was detected in livers and brains by H&E staining. ** P < 0.01, compared with LPStreated EPAC1-KO group. alone with rTNFα. A graph of the relative ratio in au of CD63 with Na + /K + -ATPase is shown. n=4 for each group (D and E). *P < 0.05, **P < 0.01. vehicle-only, rTNFα-only, rTNFα + NY173, rTNFα + IRIS-1, rTNFα + NY173 + IRIS-1, rTNFα + 740YP, and r-TNFα + NY173 + 740YP-pretreated HUVECs. n=3 for each group. *P < 0.05, **P < 0.01. ELISAs were performed to analyze the plasma vWF concentrations in C57BL/6 mice that were treated with I942. I942 was administrated at 5mg/kg/day intraperitoneally before the mouse was exposed to LPS (5 mg/kg, i.p.) or equal volume of PBS for 2 hrs. I942 down regulated the plasma vWF levels in endotoxemic mice, **P < 0.01. n=5 for each group. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 COVID-19 and its implications for thrombosis and anticoagulation Thromboinflammation and the hypercoagulability of COVID-19 COVID-19 and Acute Pulmonary Embolism in Postpartum Patient Pulmonary embolism in patients with Covid-19 pneumonia Exocytosis of Weibel-Palade bodies: how to unpack a vascular emergency kit Exchange protein directly activated by cAMP plays a critical role in regulation of vascular fibrinolysis Fibrinolysis and Inflammation in Venous Thrombus Resolution Vimentin as an integral regulator of cell adhesion and endothelial sprouting Regulation of fibrinolysis by S100A10 in vivo Regulation of von-Willebrand Factor Secretion from Endothelial Cells by the Annexin A2-S100A10 Complex Extravascular coagulation in hematopoietic stem and progenitor cell regulation Exploring traditional and nontraditional roles for thrombomodulin Activated protein C, protease activated receptor 1, and neuroprotection The Biology of Annexin A2: From Vascular Fibrinolysis to Innate Immunity Inflammation and coagulation Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells Activation of coagulation after administration of tumor necrosis factor to normal subjects The secretion of von Willebrand factor from endothelial cells; an increasingly complicated story Physiological Roles of the von Willebrand Factor-Factor VIII Interaction Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends Active von Willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome Inflammation, von Willebrand factor, and ADAMTS13 P-selectin glycoprotein ligand 1 and beta2-integrins cooperate in the adhesion of leukocytes to von Willebrand factor directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation Forskolin increases angiogenesis through the coordinated cross-talk of PKA-dependent VEGF expression and Epac-mediated PI3K/Akt/eNOS signaling Regulation of insulin receptor substrate 1 (IRS-1)/AKT kinase-mediated insulin signaling by O-Linked beta-N-acetylglucosamine in 3T3-L1 adipocytes Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy Sepsis and septic shock: endothelial molecular pathogenesis associated with vascular microthrombotic disease New insights into the mechanisms of pulmonary edema in acute lung injury Epac1 and PDZ-GEF cooperate in Rap1 mediated endothelial junction control Role of Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function Vascular endothelial-cadherin stabilizes at cell-cell junctions by anchoring to circumferential actin bundles through alpha-and beta-catenins in cyclic AMP-Epac-Rap1 signal-activated endothelial cells Increased microvascular permeability in mice lacking Epac1 (Rapgef3) Exchange protein directly activated by cAMP plays a critical role in regulation of vascular fibrinolysis The novel exchange protein activated by cyclic AMP 1 (EPAC1) agonist, I942, regulates inflammatory gene expression in human umbilical vascular endothelial cells (HUVECs) 2017) von Willebrand factor and inflammation Cyclic nucleotide analogs as probes of signaling pathways Exchange proteins directly activated by cAMP (EPACs): Emerging therapeutic targets Epac1-deficient mice have bleeding phenotype and thrombocytes with decreased GPIbβ expression A tail vein bleeding time model and delayed bleeding in hemophiliac mice Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice Protein mobilities and P-selectin storage in Weibel-Palade bodies Targeting selectins and selectin ligands in inflammation and cancer Omentin protects against LPS-induced ARDS through suppressing pulmonary inflammation and promoting endothelial barrier via an Akt/eNOSdependent mechanism The relationship between inflammation and the anticoagulant pathway: the emerging role of endothelial nitric oxide synthase (eNOS) Blood vessel injury may spur disease's fatal second phase PKA and Epac activation mediates cAMP-induced vasorelaxation by increasing endothelial NO production signalling in inflammation The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications PI3K-Akt pathway suppresses coagulation and inflammation in endotoxemic mice Caffeine induces endothelial tissue factor expression via phosphatidylinositol 3-kinase inhibition Phosphatidylinositol-3,4,5-triphosphatedependent Rac exchange factor 1 regulates epinephrine-induced exocytosis of Weibel-Palade bodies Dynein-dynactin complex mediates protein kinase A-dependent clustering of Weibel-Palade bodies in endothelial cells Small GTP-binding protein Ral is involved in cAMP-mediated release of von Willebrand factor from endothelial cells Dynamics and plasticity of Weibel-Palade bodies in endothelial cells Structure-guided design of selective Epac1 and Epac2 agonists D) vWF protein levels in the cell lysates of HUVECs incubated with I942 (30 μM) or NY173 (2 μM) for 24 hrs. au: arbitrary units of the ratio of vWF to GAPDH; NS: not significant. (E) vWF protein levels in the cell lysates of HUVECs. au: arbitrary units of the ratio of vWF to GAPDH vWF protein expression was further significantly decreased in the NY173 + rTNFα group. I942 (30 µM) significantly increased vWF expression in rTNFα-treated HUVECs 3: EPAC1 modulates the exocytosis of WPBs during inflammation Immunofluorescence of vWF in HUVECs in the non-inflammation state. (a) Negative control where normal mouse IgGs were used as primary Abs; (b) Vehicle-only treated cells NS: not significant. (B) Immunofluorescence of vWF in HUVECs in the inflammation state. HUVECs were pretreated with NY173 or I942 for 24 hrs and treated with rTNFα (50 ng/ml) for 4 hrs. (a) Vehicle only; (b) rTNFα only; (c) I942 + rTNFα; (d) NY173 + rTNFα. Scale bars, 20 µm. ImageJ was used to quantify vWF positive puncta. Five microscopic fields were examined for each case. The results were expressed as dot signals enumerated in each cell. n = 6 for each group (A and B). (C) Western immunoblotting was performed to analyze the expression of CD63, P-selectin, and the sodium potassium pump in the membrane fractions of HUVECs. Graphs of the relative ratios in arbitrary units (au) of Pselectin or CD63 with Na + /K + -ATPase are shown